Version May 2024
| Category | 2005 Recommendation | 2019 Recommendation |
| Baseline (preplacement) screening and testing | TB screening of all HCP, including a symptom evaluation and test (IGRA or TST) for those without documented prior TB disease or LTBI. | TB screening of all HCP, including a symptom evaluation and test (IGRA or TST) for those without documented prior TB disease or LTBI (unchanged); individual TB risk assessment (new). |
| Postexposure screening and testing | Symptom evaluation for all HCP when an exposure is recognized. For HCP with a baseline negative TB test and no prior TB disease or LTBI, perform a test (IGRA or TST) when the exposure is identified. If that test is negative, do another test 8 to 10 weeks after the last exposure. | Symptom evaluation for all HCP when an exposure is recognized. For HCP with a baseline negative TB test and no prior TB disease or LTBI, perform a test (IGRA or TST) when the exposure is identified. If that test is negative, do another test 8 to 10 weeks after the last exposure (unchanged). |
| Serial screening and testing for HCP without LTBI | According to health care facility and setting risk assessment. Not recommended for HCP working in low-risk health care settings. Recommended for HCP working in medium-risk health care settings and settings with potential ongoing transmission. | Not routinely recommended (new); can consider for selected HCP groups (unchanged); recommend annual TB education for all HCP (unchanged), including information about TB exposure risks for all HCP (new emphasis). |
| Evaluation and treatment of positive test results | Referral to determine whether LTBI treatment is indicated. | Treatment is encouraged for all HCP with untreated LTBI, unless medically contraindicated (new). |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
